Search results
Results from the WOW.Com Content Network
The heavily marketed diet product line Hydroxycut has been blamed in the death of at least one person and for nearly two dozen serious ailments, prompting the U.S. Food and Drug Administration to ...
Hydroxycut is a brand of dietary supplements that is marketed as a weight loss aid. Hydroxycut was originally developed and manufactured by MuscleTech Research and Development; MuscleTech was sold to Iovate Health Sciences in 2003–2004 and declared bankruptcy in 2005; Iovate continues to use MuscleTech as a brand to market Hydroxycut.
[1] Alatrofloxacin: 2006 Worldwide Serious hepatotoxicity leading to liver transplant or death. [2] Alclofenac: 1979 UK Vasculitis [3] Alpidem (Ananxyl) 1995 Worldwide Not approved in the US, withdrawn in France in 1994 [4] and the rest of the market in 1995 because of rare but serious hepatotoxicity. [3] [5] Alosetron (Lotronex) 2000 US
On May 1, 2009, the FDA issued a warning to consumers to stop using Hydroxycut products, due to 23 reports of serious health problems associated with the use of Hydroxycut, and at least one death. The FDA cited a total of 23 case reports of Hydroxycut-associated liver toxicity in their CAERS database over a seven year period from 2002 to the ...
A glitch in a version of Tandem Diabetes Care's Apple iOS app that is used with certain insulin pumps has led to over 200 injuries, prompting the FDA to issue a recall.
The FDA statement said Tandem Diabetes Care Inc. sent all affected users a letter which requested they update the software to version 2.7.1 or later, which is currently available for download in ...
FDA's role under the guidelines is to monitor company recalls and assess the adequacy of a firm's action. After a recall is completed, FDA makes sure that the product is destroyed or suitably reconditioned and investigates why the product was defective. Generally, FDA accepts reports and other necessary recall information submitted by e-mail.
(Reuters) -Advisers to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of low blood sugar.